Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless platform therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. The company has established itself as a leader in the Micro-Invasive Glaucoma Surgery (MIGS) space, launching its first MIGS device commercially in 2012. Additionally, Glaukos offers a proprietary bio-activated pharmaceutical therapy for the treatment of keratoconus, a rare corneal disorder, which was approved by the U.S. Food and Drug Administration (FDA) in 2016.
In December 2023, Glaukos received FDA approval for its first procedural pharmaceutical product, the iDose TR, an intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. The company began commercializing iDose TR in a controlled manner in February 2024.
Business Overview
Glaukos is developing a portfolio of platforms to support ongoing pharmaceutical and medical device innovations. Products and product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders such as keratoconus, dry eye and refractive vision correction, and retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
The company's primary sales-generating commercial products have been the iStent family of products and its Photrexa therapies. In the first quarter of 2024, Glaukos reported net sales of $85.6 million, up 16% from the prior year period. This growth was driven by strong performance across the company's glaucoma and corneal health franchises.
The U.S. glaucoma franchise delivered first quarter sales of $42.0 million, up 20% year-over-year, primarily due to increased volumes of the iStent family of products, including the iStent infinite. The international glaucoma franchise also performed well, with record sales of $25.2 million, up 20% on a reported basis and 21% on a constant currency basis.
Glaukos' corneal health franchise, which includes its Photrexa therapies, generated sales of $18.4 million in the first quarter, up 4% year-over-year. This growth was driven by a 7% increase in U.S. Photrexa sales, partially offset by a decline in international corneal health sales.
Financials
For the full year 2023, Glaukos reported annual net sales of $314.7 million, annual net loss of $134.7 million, annual operating cash flow of -$57.8 million, and annual free cash flow of -$78.0 million.
In the first quarter of 2024, the company reported net sales of $85.6 million, up 16% year-over-year. Gross margin for the quarter was 76%. Operating expenses for the quarter were $104.4 million, including $11.7 million in acquired in-process research and development costs. The company reported a net loss of $40.8 million for the quarter.
Glaukos has increased its full year 2024 net sales guidance range to $357 million to $365 million, up from the previous guidance of $350 million to $360 million. This revised guidance reflects the company's strong start to the year, with continued momentum expected across its glaucoma and corneal health franchises, as well as the initial contribution from the launch of the iDose TR product.
Pipeline and Growth Opportunities
Beyond its current commercial products, Glaukos has a robust pipeline of novel technologies and product candidates across its glaucoma, corneal health, and retinal disease platforms. Key pipeline programs include:
- Epioxa: The company's next-generation corneal cross-linking therapy, for which Glaukos continues to progress towards trial completion in the second Phase III pivotal trial, with data readout expected in the second half of 2024.
- iStent infinite: A PMA pivotal trial is ongoing for this product in patients with mild to moderate glaucoma.
- iLution Travoprost: A Phase IIa study is underway, with initial data readout expected later this year.
- iLink third-generation therapy: Phase II trials are ongoing.
- GLK-401: A first-in-human clinical development program for this intravitreal multi-kinase inhibitor in wet AMD patients.
- iDose TREX: The company plans to commence a Phase III study for this next-generation iDose therapy by the end of 2024.
Glaukos is also pursuing early-stage programs across new areas of glaucoma, retina, and rare disease, demonstrating the company's commitment to innovation and expanding its addressable markets.
Risks and Challenges
While Glaukos has a promising product portfolio and pipeline, the company faces several risks and challenges that investors should be aware of:
- Successful commercialization of the iDose TR product is critical to the company's future growth, and any delays or setbacks in this launch could impact financial performance.
- The company relies on a limited number of suppliers for key components and raw materials, and any disruptions in the supply chain could affect its ability to manufacture and deliver products.
- Glaukos operates in a highly regulated industry, and failure to comply with applicable regulations could result in enforcement actions, fines, or product approvals being delayed or denied.
- Reimbursement and pricing pressures from government and private payers could impact the company's ability to generate revenue from its products.
- Intense competition from larger, well-established players in the ophthalmic space could make it challenging for Glaukos to maintain its market position and pricing power.
Liquidity
As of March 31, 2024, Glaukos had $272.9 million in cash, cash equivalents, and short-term investments, along with $5.9 million in restricted cash. The company also had $283.1 million in convertible senior notes outstanding.
Glaukos' working capital, defined as total current assets less total current liabilities, was $316.4 million as of March 31, 2024, indicating the company has sufficient liquidity to fund its operations and growth initiatives in the near term.
However, the company's net cash used in operating activities was $33.9 million in the first quarter of 2024, and its free cash flow was -$78.0 million for the full year 2023, reflecting the significant investments Glaukos is making in research and development, as well as the commercialization of its products.
Conclusion
Glaukos is a promising ophthalmic innovator with a diverse portfolio of commercial products and a robust pipeline of novel technologies. The company's recent FDA approval and controlled launch of the iDose TR product, coupled with the strong performance of its glaucoma and corneal health franchises, position Glaukos for continued growth in the years ahead.
While the company faces risks and challenges common to the highly regulated medical device and pharmaceutical industries, Glaukos' commitment to innovation, its expanding global footprint, and its strong financial position suggest it is well-equipped to navigate these obstacles and deliver value for shareholders over the long term.